CClinicalTrials.gg
WithdrawnNCT06738628Updated Oct 1, 2026

Disposable Endoscope Platform in Third Space Endoscopic Procedures

An observational study in Achalasia and Gastroparesis, sponsored by Baylor College of Medicine. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Baylor College of Medicine · Observational

Why this study was withdrawn
The study was closed by the investigator prior to enrollment of any participants. The IRB has been notified and the study is closed.
Updated Oct 1, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, single-arm unblinded study performed at a single tertiary center in the United States. All subjects will receive standard medical care and no experimental interventions are going to be performed. The procedures will be performed by Dr. Mohamed Othman, Dr. Salmaan Jawaid, Dr. Tara Keihanian, and Dr. Fares Ayoub. All patients undergoing third space endoscopic procedures including e-POEM and g-POEM, meeting study inclusion criteria will be screened by study coordinators for preliminary eligibility and those who meet the inclusion criteria will be approached individually for further discussion about the study and obtaining informed consent.

The goal of this prospective, pilot trial is to demonstrate the efficacy, feasibility, safety, and clinical outcomes of third space endoscopic procedures completed using a disposable endoscope platform.

Read the detailed description

Over the past decade, therapeutic endoscopy has rapidly progressed giving rise to the fields of third space endoscopy and endoscopic surgery. In the foregut, esophageal per-oral endoscopic myotomy (e-POEM) has become the standard approach for achalasia with level I data supporting its use1. For gastroparesis, randomized clinical trial data 2 now supports gastric POEM (g-POEM) use for refractory cases with promising results particularly in diabetic and post-surgical patients.

Despite the remarkable advances in endoscopic therapy, there has been comparably slower progress in innovation for endoscopic platforms. In fact, current endoscope design is not significantly different from the earliest endoscopes where tip deflection is primarily controlled by rotating dials on the shaft of the endoscope and insufflation and suction are controlled by manual pressure-controlled buttons. Original fiberoptic gastroscopes were designed to facilitate diagnostic use, where the endoscopist manipulates tip-deflection dials using both hands while viewing the intestinal mucosa through a viewer, with an assistant moving the shaft of the endoscope. This same design was then adapted for colonoscopy, and later for duodenoscopy and endoscopic ultrasound. Despite significant progress in image quality, the endoscope remains a heavy device, requiring significant dexterity and musculoskeletal fitness on behalf of the endoscopist to perform endoscopy ergonomically without risking muscle injury. In addition, endoscopes require several supportive devices to function, including a separate water pump, video processor, computer screen and if needed an electrosurgical generator, making the portability of traditional endoscopic platforms quite limited.

More recently, rising concerns about infectious complications from reusable endoscopes have led to the development of several single-use endoscope platforms. A novel disposable endoscope (AMBU single-use disposable gastroscope; AMBU USA, Columbia, Md, USA) was recently approved by the U.S. Food \& Drug Administration (FDA) in 2022 for use in humans. This endoscopic platform is designed for single use and comes with several advantages compared to traditional reusable endoscopes. The platform is significantly lighter, with a weight of 650 grams compared to a traditional reusable upper endoscope which weighs approximately 3900 grams. Additionally, the single use platform has a wider depth of field and significantly smaller video processor and built in portable screen. These advantages have led our group to use the endoscope for therapeutic foregut procedures including e-POEM and g-POEM with positive results. The investigators at Baylor College of Medicine most recently published a proof-of-concept experience 3 in using the disposable gastroscope for a case of e-POEM, where the significantly lighter weight of the endoscope allowed easier maneuverability and subjectively lower musculoskeletal strain for the performing endoscopist, with no negative effects on image quality or technical aspects of the procedure.

Before wider adoption, these perceived benefits need to be demonstrated in a larger, prospective trial confirming non-inferiority to historical data from reusable platforms and safety.

02

Conditions studied

  • Achalasia
  • Gastroparesis

Keywords

  • Per-Oral Endoscopic Myotomy
  • Gastric Per-Oral Endoscopic Myotomy
  • Disposable Endoscope
03

In context

Esophageal Achalasia

140 studies on the registry are indexed under Esophageal Achalasia; 44 are open to participants now.

Browse Esophageal Achalasia studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 734 studies on the registry; 110 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 44 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients 18 years or older, not pregnant (if a woman), consenting to the study, and presents for an Esophageal POEM, or Gastric POEM will be invited to participate on this study.

Inclusion criteria

  1. Patient is ≥ 18 years old.
  2. Patients can provide informed consent.
  3. Patient is referred for third space endoscopic procedure including e-POEM, g-POEM.

Exclusion criteria

Exclusion Criteria:

  1. Patient is \< 18 years old.
  2. Patient refused and/or unable to provide consent.
  3. Patient is a pregnant woman.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
4 Weeks
Patient registry
Yes

Interventions

  • Procedure(Esophageal or Gastric) Per-Oral Endoscopic Myotomy

    Performing Per-Oral Endoscopic Myotomy for the treatment of either achalasia of the esophagus, or gastroparesis of the stomach.

    Also known as: POEM

06

What researchers measure

Primary outcomes

  1. Technical Success

    Defined as the ability to perform entire myotomy (procedure) with the disposable endoscope.

    Time frame: Day 1 (procedure day)

Secondary outcomes

  1. Total Procedure Time

    Total recorded time to perform procedure using disposable endoscope

    Time frame: During Procedure

  2. Intraprocedural adverse events

    Adverse events emerging during procedure

    Time frame: During Procedure

  3. Satisfactory scores on Endoscopist satisfaction

    Satisfactory survey: with endoscope maneuverability (1-5 Likert scale; 1 being "strongly disagree" to 5 being "strongly agree"), with endoscope functionality \[insufflation, suction, accessory passage\] (1-5 Likert scale), with endoscope image quality (1-5 Likert scale; 1 being "strongly disagree" to 5 being "strongly agree").

    Time frame: Immediately following completion of the procedure

  4. Scores on musculoskeletal strain survey

    Musculoskeletal Strain survey: Focused on Overall strain, wrist strain, shoulders strain, and neck strain

    Time frame: Immediately following completion of the procedure

07

Study locations

1 site
  • Baylor College of Medicine
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No — There are no plans to share IPD to other researchers.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Withdrawn The study was closed by the investigator prior to enrollment of any participants. The IRB has been notified and the study is closed.
changed Oct 1, 2026
Start date
May 30, 2026→Dec 30, 2026
Oct 1, 2026
Primary completion
Oct 31, 2026→Sep 30, 2027
Oct 1, 2026
Study completion
Mar 31, 2027→Dec 31, 2027
Oct 1, 2026
Enrollment
40 (estimated)→0 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Withdrawn
    Why stopped The study was closed by the investigator prior to enrollment of any participants. The IRB has been notified and the study is closed.
    Start date May 30, 2026→Dec 30, 2026
    Primary completion Oct 31, 2026→Sep 30, 2027
    Study completion Mar 31, 2027→Dec 31, 2027
    Enrollment 40 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06738628
Lead sponsor
Baylor College of Medicine
Responsible party
Mohamed Othman, MD (Principal Investigator, Baylor College of Medicine) — Principal investigator
First posted
Dec 17, 2024
Start date
Dec 30, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Mohamed Othman, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion